Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics  was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Company Growth (employees)
Type
Public
HQ
Hampton, US
Size (employees)
196 (est)
Celldex Therapeutics is headquartered in Hampton, US

Key People at Celldex Therapeutics

Anthony S. Marucci

Anthony S. Marucci

Founder, President & CEO
Avery W. Catlin

Avery W. Catlin

SVP & CFO
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

SVP & CMO
Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Harry H. Penner

Harry H. Penner

Co - Founder

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
220 53 I 78 Frontage Rd
Needham, US
119 4th Ave
Fall River, US
U Mass Dartmouth Center For Innovation & Entrepreneurship 151 Martine St
Branford, US
1a 688 E Main St

Celldex Therapeutics Data and Metrics

Celldex Therapeutics Financial Metrics

Celldex Therapeutics's revenue was reported to be $1.5 m in Q1, 2017
USD

Revenue (Q1, 2017)

1.5 m

Net income (Q1, 2017)

(34.3 m)

EBIT (Q1, 2017)

(35.1 m)

Market capitalization (21-Jul-2017)

289.4 m

Cash (31-Mar-2017)

42.5 m
Celldex Therapeutics's current market capitalization is $289.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

4.1 m3.6 m5.5 m

Revenue growth, %

(13%)53%

Operating expense total

85.6 m126 m135 m

EBIT

(81.4 m)(122.4 m)(129.5 m)

EBIT margin, %

(1981%)(3414%)(2364%)

Net Income

(81.6 m)(118.1 m)(127.2 m)(128.5 m)
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

592 k1.1 m2.2 m1 m1.3 m1.4 m2.2 m1.5 m

R&D expense

24.1 m26.2 m26.5 m24.7 m27.4 m25.7 m25 m25.8 m

General and administrative expense

4.8 m5 m8.2 m8.5 m9.3 m7.8 m7 m7.2 m

Operating expense total

28.9 m31.2 m34.7 m33.1 m36.8 m33.5 m32 m33 m

EBIT

(28.5 m)(30.3 m)(32.8 m)(32.4 m)(35.7 m)(32.4 m)(30 m)(35.1 m)

EBIT margin, %

(4822%)(2756%)(1504%)(3155%)(2740%)(2330%)(1351%)(2289%)

Net Income

(28.3 m)(28.1 m)(32.4 m)(32 m)(34.7 m)(32 m)(29.6 m)(34.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

169.4 m28 m72.1 m42.5 m

Accounts Receivable

489 k427 k97 k1.8 m

Current Assets

305.2 m205 m294.9 m195.6 m

PP&E

10 m10.5 m11.5 m13.2 m

Goodwill

9 m9 m9 m91 m

Total Assets

347.1 m248 m337.6 m383.4 m

Accounts Payable

2.2 m2.6 m1.5 m1.7 m

Current Liabilities

20.4 m24.5 m30.2 m35.2 m

Total Liabilities

117.9 m

Additional Paid-in Capital

662.7 m672.7 m878.7 m982.3 m

Retained Earnings

(345.7 m)(463.8 m)(591 m)(719.5 m)

Total Equity

319.8 m211.7 m290.1 m265.4 m

Financial Leverage

1.1 x1.2 x1.2 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2017

Cash

40.8 m32.5 m42.5 m

Current Assets

255.6 m229.8 m173.5 m

PP&E

10.6 m10.7 m12.4 m

Goodwill

9 m9 m91 m

Total Assets

297.6 m271.7 m360 m

Accounts Payable

1.2 m1.7 m2.7 m

Current Liabilities

21.2 m21.6 m27 m

Additional Paid-in Capital

666.3 m668.6 m998.9 m

Retained Earnings

(403.9 m)(431.9 m)(753.7 m)

Total Equity

265.3 m239.4 m247.8 m

Financial Leverage

1.1 x1.1 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(81.6 m)(118.1 m)(127.2 m)(128.5 m)

Depreciation and Amortization

1.9 m2.4 m3 m3.1 m

Accounts Payable

7.2 m1.5 m4.9 m(5 m)

Cash From Operating Activities

(67.7 m)(101.5 m)(98.9 m)(113 m)

Purchases of PP&E

(4.2 m)(1.9 m)(4.9 m)(2.8 m)

Cash From Investing Activities

(77.4 m)(41 m)(50.2 m)68.9 m

Cash From Financing Activities

289.6 m1.2 m193.2 m14.5 m

Interest Paid

1.2 m1.2 m1.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(28.3 m)(28.1 m)(32.4 m)(32 m)(34.7 m)(32 m)(29.6 m)(34.3 m)

Accounts Payable

1.2 m1.7 m3.1 m2 m1.2 m2.6 m706 k1 m2.7 m
USDY, 2017

Revenue/Employee

7.8 k

Financial Leverage

1.5 x

Celldex Therapeutics Operating Metrics

FY, 2016

Patents Issued

300

Celldex Therapeutics Market Value History

Celldex Therapeutics Company Life and Culture

You may also be interested in